Archives: “Archives”

Showing 1 - 10 of 31 posts

The Role of Glycosylation in Inflammatory Bowel Disease

https://www.coltonconsortium.org/projects/the-role-of-glycosylation-in-inflammatory-bowel-disease/

Investigating how foreign sugar modifications on anti-TNF biologics trigger immune responses in pediatric IBD patients, this project aims to personalize biologic therapy selection and inform safer drug design.

Shedding Light on the Invisible: A New Paradigm for Predicting Multiple Sclerosis Disease Progression Using Novel MRI Tools for Probing Pathology in Normal Appearing Tissues

https://www.coltonconsortium.org/projects/shedding-light-on-the-invisible-a-new-paradigm-for-predicting-multiple-sclerosis-disease-progression-using-novel-mri-tools-for-probing-pathology-in-normal-appearing-tissues/

Applying advanced quantitative MRI to detect pathology invisible to current clinical tools, this project builds an AI model to predict MS progression and enable earlier, more personalized diagnosis and treatment.

Novel Tools to Track and Manipulate Immune Cells in Autoimmunity Models

https://www.coltonconsortium.org/projects/novel-tools-to-track-and-manipulate-immune-cells-in-autoimmunity-models/

Developing a cell-labeling tool to map immune cell interactions in living tissue, this project identifies the drivers of skin-resident T cell persistence in psoriasis and potential targets for disease prevention.

Early Detection and Diagnosis of Autoimmune Diseases Using Foundation AI Models

https://www.coltonconsortium.org/projects/early-detection-and-diagnosis-of-autoimmune-diseases-using-foundation-ai-models/

Applying self-supervised AI to multi-modal electronic health records — integrating clinical notes, labs, and imaging — this project builds scalable diagnostic models to detect autoimmune diseases earlier and more precisely.

Developing New Mode-of-Action Calcineurin Inhibitors for Acute Colitis Therapeutics

https://www.coltonconsortium.org/projects/developing-new-mode-of-action-calcineurin-inhibitors-for-acute-colitis-therapeutics/

Targeting the calcineurin-NFAT protein-protein interaction rather than enzyme active sites, this project develops a novel class of inhibitors to treat steroid-refractory ulcerative colitis with fewer side effects.

The Epidermis as a Novel Therapeutic Target in Pemphigus Vulgaris

https://www.coltonconsortium.org/projects/the-epidermis-as-a-novel-therapeutic-target-in-pemphigus-vulgaris/

By profiling genetic and molecular drivers of pemphigus vulgaris across patient skin and blood, this project uncovers genotype-driven inflammatory loops and actionable targets for personalized therapy.

Developing a Multi-parameter Prognostic Prediction Model for Disability Ranks and Progression of Patients with Multiple Sclerosis at the Early Stages of the Disease

https://www.coltonconsortium.org/projects/developing-a-multi-parameter-prognostic-prediction-model-for-disability-ranks-and-progression-of-patients-with-multiple-sclerosis-at-the-early-stages-of-the-disease/

Integrating clinical, imaging, and biological data from large real-world MS cohorts, this project builds a machine learning model to predict disability progression early and enable personalized treatment decisions.

Immunotherapy-Related Adverse Effects as Models for Fragile Tolerance in Humans

https://www.coltonconsortium.org/projects/immunotherapy-related-adverse-effects-as-models-for-fragile-tolerance-in-humans/

Using cancer patients experiencing immunotherapy-triggered autoimmunity as a unique human model, this project uncovers the molecular and epigenetic mechanisms by which self-reactive T cells escape immune tolerance.

Inhibiting NETosis with Nuclear-Penetrating Antibodies

https://www.coltonconsortium.org/projects/inhibiting-netosis-with-nuclear-penetrating-antibodies/

Repurposing nuclear-penetrating autoantibodies from lupus and scleroderma patients as potent, safe inhibitors of pathogenic NETosis.